Clinical practice patterns for upper tract urothelial carcinoma: a nationwide survey in Japan

被引:18
|
作者
Kikuchi, Eiji [1 ]
Oya, Mototsugu [1 ]
机构
[1] Keio Univ, Sch Med, Dept Urol, Tokyo, Japan
关键词
clinical management; nationwide survey; renal pelvic tumor; upper tract urothelial carcinoma; ureteral tumor; UPPER URINARY-TRACT; NEOADJUVANT CHEMOTHERAPY; NEPHROURETERECTOMY; ASSOCIATION; CARBOPLATIN; PREVENTION; GUIDELINES; ADJUVANT; TUMORS; TRIAL;
D O I
10.1093/jjco/hyw072
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: A comprehensive survey has not yet been conducted to investigate care patterns by urologists for the management of upper tract urothelial carcinoma. Methods: We conducted a nationwide survey for urologists treating upper tract urothelial carcinoma patients. The questionnaire was approved by the Japanese Urological Association and sent by mail in February 2014 to 1119 institutes in Japan. We identified 627 responders for this study. Results: Our survey demonstrated that ( i) the mean number of radical nephroureterectomy cases per institution in 2013 was 7.6, ( ii) the main detecting tool for upper tract urothelial carcinoma is contrast-enhanced computed tomography, ( iii) the need for ureteroscopic evaluations is highly dependent on voiding urine cytology results, ( iv) 67% of urologists always or often perform radical nephroureterectomy by laparoscopic surgery, ( v) more than half of the urologists do not aggressively perform lymph node dissection, ( vi) 75% of the urologists perform bladder cuff incision through an extravesical approach, ( vii) urologists perform kidney-sparing surgery following various indications, ( viii) 59% of the urologists always perform adjuvant systemic chemotherapy for high-risk upper tract urothelial carcinoma patients, ( ix) the combination of gemcitabine and cisplatin is the most frequent chemo-regimen for metastatic upper tract urothelial carcinoma, and gemcitabine and cisplatin with dose reductions is also the first choice even in patients with impaired renal function and ( x) 10.5% of urologists always or sometimes perform single intravesical chemotherapy immediately after radical nephroureterectomy. Conclusions: The management strategy for upper tract urothelial carcinoma has changed with the introduction of new devices and development of instruments. The lack of clear evidence for relatively uncommon upper tract urothelial carcinoma affects the consistency of its treatment strategies.
引用
下载
收藏
页码:768 / 774
页数:7
相关论文
共 50 条
  • [21] A NATIONWIDE SURVEY ON CLINICAL PRACTICE PATTERNS AND BLEEDING COMPICATIONS OF PERCUTANEOUS NATIVE KIDNEY BIOPSY IN JAPAN
    Kawaguchi, Takehiko
    Nagasawsa, Tasuku
    Tsuruya, Kazuhiko
    Miura, Kenichiro
    Katsuno, Takayuki
    Morikawa, Takashi
    Ishikawa, Eiji
    Ogura, Masao
    Matsumura, Hideki
    Kurayama, Ryota
    Matsumoto, Shinsuke
    Marui, Yuhji
    Hara, Shigeo
    Maruyama, Shoichi
    Narita, Ichiei
    Okada, Hirokazu
    Ubara, Yoshifumi
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34
  • [22] A nationwide survey on clinical practice patterns and bleeding complications of percutaneous native kidney biopsy in Japan
    Kawaguchi, Takehiko
    Nagasawsa, Tasuku
    Tsuruya, Kazuhiko
    Miura, Kenichiro
    Katsuno, Takayuki
    Morikawa, Takashi
    Ishikawa, Eiji
    Ogura, Masao
    Matsumura, Hideki
    Kurayama, Ryota
    Matsumoto, Shinsuke
    Marui, Yuhji
    Hara, Shigeo
    Maruyama, Shoichi
    Narita, Ichiei
    Okada, Hirokazu
    Ubara, Yoshifumi
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2020, 24 (05) : 389 - 401
  • [23] Neoadjuvant versus adjuvant chemotherapy in upper tract urothelial carcinoma: A nationwide cohort study
    Tae, Jong Hyun
    Ha, Moon Soo
    Chi, Byung Hoon
    Chang, In Ho
    Kim, Tae-Hyoung
    Myung, Soon Chul
    Nguyen, Tuan Thanh
    Kim, Myoungsuk
    Lee, Kyung-Eun
    Kim, Yuwon
    Woo, Hyun-Ki
    Kyoung, Dae-Sung
    Kim, Hasung
    Choi, Se Young
    BMC UROLOGY, 2022, 22 (01)
  • [24] Neoadjuvant versus adjuvant chemotherapy in upper tract urothelial carcinoma: A nationwide cohort study
    Jong Hyun Tae
    Moon Soo Ha
    Byung Hoon Chi
    In Ho Chang
    Tae-Hyoung Kim
    Soon Chul Myung
    Tuan Thanh Nguyen
    Myoungsuk Kim
    Kyung-Eun Lee
    Yuwon Kim
    Hyun-ki Woo
    Dae-Sung Kyoung
    Hasung Kim
    Se Young Choi
    BMC Urology, 22
  • [25] Contemporary patterns of presentation, diagnostics and management of upper tract urothelial cancer in 101 centres: the Clinical Research Office of the Endourological Society Global upper tract urothelial carcinoma registry
    Baard, Joyce
    Cormio, Luigi
    Cavadas, Vitor
    Alcaraz, Antonio
    Shariat, Shahrokh F.
    de la Rosette, Jean
    Laguna, Maria P.
    CURRENT OPINION IN UROLOGY, 2021, 31 (04) : 354 - 362
  • [26] Clinical Implications of the Molecular and Genomic Landscape of Upper Tract Urothelial Carcinoma
    Salvador Jaime-Casas
    Abhishek Tripathi
    Sumanta K. Pal
    Wesley Yip
    Current Urology Reports, 2025, 26 (1)
  • [27] The clinical impact of ureteroscopy for upper tract urothelial carcinoma: A multicenter study
    Hayakawa, Nozomi
    Kikuchi, Eiji
    INTERNATIONAL JOURNAL OF UROLOGY, 2024, 31 (04) : 402 - 403
  • [28] Copy Number Signatures and Clinical Outcomes in Upper Tract Urothelial Carcinoma
    Guan, Bao
    Liang, Yuan
    Lu, Huan
    Xu, Zhengzheng
    Shi, Yue
    Li, Juan
    Kong, Wenwen
    Tian, Chuanyu
    Tan, Yezhen
    Gong, Yanqing
    Liu, Jin
    Fang, Dong
    Shen, Qi
    He, Shiming
    Shakeel, Muhammad
    Zhang, Zhongyuan
    He, Qun
    Li, Xuesong
    Ci, Weimin
    Zhou, Liqun
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
  • [29] Epidemiology, clinical presentation, and evaluation of upper-tract urothelial carcinoma
    Petros, Firas G.
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2020, 9 (04) : 1794 - 1798
  • [30] Treatment Patterns, Outcomes, and Costs Associated With Localized Upper Tract Urothelial Carcinoma
    Fero, Katherine E.
    Shan, Yong
    Lec, Patrick M.
    Sharma, Vidit
    Srinivasan, Aditya
    Movva, Giri
    Baillargeon, Jacques
    Chamie, Karim
    Williams, Stephen B.
    JNCI CANCER SPECTRUM, 2021, 5 (06)